原始出處紀錄
決策級主要結果 (Topline)
INmune Bio：XPro1595 在 Ph2 MINDFuL 阿茲海默症試驗中達到白質 MRI 終點
Phase 2 MINDFuL 試驗達到其探索性 chi-separation MRI 白質生物標記終點，在完整 mITT 族群中顯示具統計學意義的治療效果（p=0.0028, d=0.46, n=200），在發炎富集子群中效果更強（p=0.0098, d=0.59, n=100）。此結果驗證對髓鞘的靶點接合，並支持即將展開的 Phase 2b/3 註冊性計畫的精準醫療策略。
關鍵事實
來源摘錄
EX-99.1 2 ea029332501ex99-1.htm PRESS RELEASE DATED JUNE 2, 2026 Exhibit 99.1 INmune Bio Reports Statistically Significant Treatment Effect on Advanced White Matter MRI Biomarker in Phase 2 MINDFuL Alzheimer’s Trial XPro1595 showed a highly significant treatment effect in the full mITT population (p=0.0028; d=0.46; n=200), demonstrating broad tissue-level target engagement and treatment-related biological effect. Efficacy was further strengthened in biomarker-enriched patients with elevated levels of inflammation (p=0.0098; d=0.59; n=100) validating INmune’s precision-medicine approach and directly aligning with the design of the Phase 2b/3 registrational program. BOCA RATON, FL , June 02, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB), a late-stage biotechnology company fo